AU2021349301A1 - Canine antibody variants - Google Patents

Canine antibody variants Download PDF

Info

Publication number
AU2021349301A1
AU2021349301A1 AU2021349301A AU2021349301A AU2021349301A1 AU 2021349301 A1 AU2021349301 A1 AU 2021349301A1 AU 2021349301 A AU2021349301 A AU 2021349301A AU 2021349301 A AU2021349301 A AU 2021349301A AU 2021349301 A1 AU2021349301 A1 AU 2021349301A1
Authority
AU
Australia
Prior art keywords
igg
antibody
constant domain
canine
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021349301A
Other languages
English (en)
Inventor
Lisa Marie BERGERON
Henry Luis CAMPOS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services LLC filed Critical Zoetis Services LLC
Publication of AU2021349301A1 publication Critical patent/AU2021349301A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2021349301A 2020-09-28 2021-09-28 Canine antibody variants Pending AU2021349301A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063084241P 2020-09-28 2020-09-28
US63/084,241 2020-09-28
PCT/US2021/052338 WO2022067233A2 (en) 2020-09-28 2021-09-28 Canine antibody variants

Publications (1)

Publication Number Publication Date
AU2021349301A1 true AU2021349301A1 (en) 2023-08-24

Family

ID=78599123

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021349301A Pending AU2021349301A1 (en) 2020-09-28 2021-09-28 Canine antibody variants

Country Status (16)

Country Link
EP (1) EP4217384A2 (https=)
JP (1) JP2023543262A (https=)
KR (1) KR20230079148A (https=)
CN (1) CN116438196A (https=)
AR (1) AR123636A1 (https=)
AU (1) AU2021349301A1 (https=)
BR (1) BR112023005393A2 (https=)
CA (1) CA3194936A1 (https=)
CL (2) CL2023000878A1 (https=)
CO (1) CO2023004102A2 (https=)
EC (1) ECSP23030271A (https=)
IL (1) IL301413A (https=)
MX (1) MX2023003624A (https=)
PE (1) PE20231374A1 (https=)
TW (1) TW202229337A (https=)
WO (1) WO2022067233A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115996949A (zh) * 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体
KR20250026186A (ko) * 2022-06-21 2025-02-25 조에티스 서비시즈 엘엘씨 갯과 항체 돌연변이체
JP2026508096A (ja) 2023-01-20 2026-03-10 ゾエティス・サービシーズ・ユーケー・リミテッド 治療抗体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
CN113194984A (zh) * 2018-10-18 2021-07-30 金德雷德生物科学股份有限公司 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体
EP3887397A1 (en) * 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CN113227134A (zh) * 2018-12-05 2021-08-06 株式会社梅花治疗 抗体的Fc区变体
US11542333B2 (en) * 2019-01-03 2023-01-03 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
CN115996949A (zh) * 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体

Also Published As

Publication number Publication date
CL2024000628A1 (es) 2024-07-19
AR123636A1 (es) 2022-12-28
CA3194936A1 (en) 2022-03-31
US20240010716A1 (en) 2024-01-11
MX2023003624A (es) 2023-04-11
WO2022067233A3 (en) 2022-05-27
PE20231374A1 (es) 2023-09-07
KR20230079148A (ko) 2023-06-05
ECSP23030271A (es) 2023-07-31
CL2023000878A1 (es) 2023-10-20
IL301413A (en) 2023-05-01
EP4217384A2 (en) 2023-08-02
JP2023543262A (ja) 2023-10-13
BR112023005393A2 (pt) 2023-04-25
TW202229337A (zh) 2022-08-01
CN116438196A (zh) 2023-07-14
WO2022067233A2 (en) 2022-03-31
CO2023004102A2 (es) 2023-04-05

Similar Documents

Publication Publication Date Title
US20230242635A1 (en) Canine antibody variants
US20250026834A1 (en) Feline antibody variants
AU2021400322A1 (en) Mutations in feline antibody constant regions
EP4217384A2 (en) Canine antibody variants
EP4512416A2 (en) Mutations in canine antibody constant regions
EP4711383A2 (en) Feline antibody variants
US12612454B2 (en) Canine antibody variants
US12612455B2 (en) Feline antibody variants
RU2840969C1 (ru) Варианты кошачьих антител
HK40121344A (en) Mutations in canine antibody constant regions
BR122024006370A2 (pt) Polipeptídeo, seu uso, composição farmacêutica, kit, igg modificada, vetor, célula isolada, molécula de fusão, e seu método de fabricação

Legal Events

Date Code Title Description
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 28 JUL 2023